Trigonelline inhibits intestinal microbial metabolism of choline and its associated cardiovascular risk

Jul 7, 2018Journal of pharmaceutical and biomedical analysis

Trigonelline reduces gut bacteria’s processing of choline linked to heart disease risk

AI simplified

Abstract

Trigonelline reduced trimethylamine-N-oxide (TMAO) production by 85.3% at a concentration of 300 μg/mL.

  • Gut bacteria convert choline into trimethylamine (TMA), which is then transformed into TMAO, a compound associated with cardiovascular disease.
  • Trigonelline was isolated from the seeds of Trigonella foenum-graecum and characterized with a purity of 87.26%.
  • Citrobacter freundii was identified as a key bacterium responsible for TMA production in the gut.
  • In vitro experiments showed that adding trigonelline to cultures of C. freundii significantly decreased TMA and TMAO levels.
  • Mice studies indicated that oral administration of trigonelline altered serum lipid and TMAO levels in a dose-dependent manner.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free